Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer
Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer
- A 49-year-old women was referred for biopsy after routine mammography showed a 2.4-cm diameter spiculated mass in the left breast
- PE: revealed a well-circumscribed, non-tender firm mass in the lower-outer quadrant of the left breast; singular palpable nodal enlargement in the left axilla
- Excisional biopsy of the breast and axillary lymph nodes showed high grade lobular carcinoma
- ER-/PR-; HER2 IHC 3+; Ki-67, 89%
- Staging, pT2N3M0
- She underwent right mastectomy and lymph node dissection
- The patient was started on adjuvant chemotherapy with docetaxel + carboplatin with 12 months of trastuzumab + pertuzumab
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020Podcast
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
